APA (7th ed.) Citation

LeVee, A., Spector, K., Larkin, B., Dezem, F., Plummer, J., Dadmanesh, F., . . . McArthur, H. L. (2023). Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer. Cancer Medicine, 12(9), 10647. https://doi.org/10.1002/cam4.5817

Chicago Style (17th ed.) Citation

LeVee, Alexis, Kellie Spector, Brigid Larkin, Felipe Dezem, Jasmine Plummer, Farnaz Dadmanesh, Sujata Patil, and Heather L. McArthur. "Incidence and Prognostic Impact of HER2‐positivity Loss After Dual HER2‐directed Neoadjuvant Therapy for HER2+ Breast Cancer." Cancer Medicine 12, no. 9 (2023): 10647. https://doi.org/10.1002/cam4.5817.

MLA (9th ed.) Citation

LeVee, Alexis, et al. "Incidence and Prognostic Impact of HER2‐positivity Loss After Dual HER2‐directed Neoadjuvant Therapy for HER2+ Breast Cancer." Cancer Medicine, vol. 12, no. 9, 2023, p. 10647, https://doi.org/10.1002/cam4.5817.